BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 35865011)

  • 1. CCR5 as a Prognostic Factor in Lower-Grade Glioma is Involved in the Remodeling of the Tumor Microenvironment.
    Wang F; Tao Z; Tian Z; Jin J; Dong J; Dai Y; Yu W; Tang B; Hu S
    Front Genet; 2022; 13():874896. PubMed ID: 35865011
    [No Abstract]   [Full Text] [Related]  

  • 2. Screening TCGA database for prognostic genes in lower grade glioma microenvironment.
    Ni J; Liu S; Qi F; Li X; Yu S; Feng J; Zheng Y
    Ann Transl Med; 2020 Mar; 8(5):209. PubMed ID: 32309356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-Related Gene SERPINE1 Is a Novel Biomarker for Diffuse Lower-Grade Gliomas
    Huang X; Zhang F; He D; Ji X; Gao J; Liu W; Wang Y; Liu Q; Xin T
    Front Oncol; 2021; 11():646060. PubMed ID: 34094933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IRF7 as an Immune-Related Prognostic Biomarker and Associated with Tumor Microenvironment in Low-Grade Glioma.
    Peng S; Wang G; Cheng Z; Guo Z
    Int J Gen Med; 2021; 14():4381-4393. PubMed ID: 34413671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Prognostic Microenvironment-Related Immune Signature
    Qiu H; Li Y; Cheng S; Li J; He C; Li J
    Front Oncol; 2020; 10():580263. PubMed ID: 33425732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of tumor microenvironment-related genes in lower-grade gliomas by mining TCGA database.
    Liang H; Huang C
    Transl Cancer Res; 2020 Aug; 9(8):4583-4595. PubMed ID: 35117823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant Tumor Purity Reveals the Driven and Prognostic Role of
    Lu X; Li C; Xu W; Wu Y; Wang J; Chen S; Zhang H; Huang H; Huang H; Liu W
    Front Oncol; 2021; 11():676124. PubMed ID: 34557404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Iron Metabolism-Related Genes as Prognostic Indicators for Lower-Grade Glioma.
    Xu S; Wang Z; Ye J; Mei S; Zhang J
    Front Oncol; 2021; 11():729103. PubMed ID: 34568059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma.
    Qiu H; Tian W; He Y; Li J; He C; Li Y; Liu N; Li J
    Front Oncol; 2021; 11():654350. PubMed ID: 33954112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of the prognostic and role in immune cell infiltration of MSR1 expression in lower-grade gliomas.
    Ji Q; Huang K; Jiang Y; Lei K; Tu Z; Luo H; Zhu X
    Cancer Med; 2022 May; 11(9):2020-2035. PubMed ID: 35142109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.
    Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S
    Front Immunol; 2023; 14():1128244. PubMed ID: 37818357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New biomarker: the gene HLA-DRA associated with low-grade glioma prognosis.
    Chen D; Yao J; Hu B; Kuang L; Xu B; Liu H; Dou C; Wang G; Guo M
    Chin Neurosurg J; 2022 May; 8(1):12. PubMed ID: 35585639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combined signatures of telomere and immune cell landscape provide a prognostic and therapeutic biomarker in glioma.
    Han X; Yan Z; Fan K; Guan X; Hu B; Li X; Ou Y; Cui B; An L; Zhang Y; Gong J
    Front Immunol; 2023; 14():1220100. PubMed ID: 37662954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of γ-aminobutyric acidergic synapse-associated signature for lower-grade gliomas.
    Jiang H; Sun Z; Li F; Chen Q
    Front Immunol; 2022; 13():983569. PubMed ID: 36405708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Verification of Glutamatergic Synapse-Associated Prognosis Signature for Lower-Grade Gliomas.
    Ye L; Xu Y; Hu P; Wang L; Yang J; Yuan F; Wang Y; Zhang C; Tian D; Chen Q
    Front Mol Neurosci; 2021; 14():720899. PubMed ID: 34776862
    [No Abstract]   [Full Text] [Related]  

  • 19. Comprehensive Characterization of a Novel E3-Related Gene Signature With Implications in Prognosis and Immunotherapy of Low-Grade Gliomas.
    Tan S; Spear R; Zhao J; Sun X; Wang P
    Front Genet; 2022; 13():905047. PubMed ID: 35832194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
    Zhao WJ; Ou GY; Lin WW
    Front Immunol; 2021; 12():682415. PubMed ID: 34054873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.